55 related articles for article (PubMed ID: 38683349)
21. Recent Advancements in CT and MR Imaging of Prostate Cancer.
Daryanani A; Turkbey B
Semin Nucl Med; 2022 May; 52(3):365-373. PubMed ID: 34930627
[TBL] [Abstract][Full Text] [Related]
22. An Improved
Mease RC; Kang CM; Kumar V; Banerjee SR; Minn I; Brummet M; Gabrielson KL; Feng Y; Park A; Kiess AP; Sgouros G; Vaidyanathan G; Zalutsky MR; Pomper MG
J Nucl Med; 2022 Feb; 63(2):259-267. PubMed ID: 34088772
[TBL] [Abstract][Full Text] [Related]
23. Synthesis, Preclinical Evaluation, and First-in-Human PET Study of Quinoline-Containing PSMA Tracers with Decreased Renal Excretion.
Zhang X; Wu Y; Zeng Q; Xie T; Yao S; Zhang J; Cui M
J Med Chem; 2021 Apr; 64(7):4179-4195. PubMed ID: 33783213
[TBL] [Abstract][Full Text] [Related]
24. Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer.
Farolfi A; Calderoni L; Mattana F; Mei R; Telo S; Fanti S; Castellucci P
J Nucl Med; 2021 May; 62(5):596-604. PubMed ID: 33712536
[TBL] [Abstract][Full Text] [Related]
25. The value of
Hong JJ; Liu BL; Wang ZQ; Tang K; Ji XW; Yin WW; Lin J; Zheng XW
EJNMMI Res; 2020 Nov; 10(1):138. PubMed ID: 33169183
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and Evaluation of a Macrocyclic Actinium-225 Chelator, Quality Control and In Vivo Evaluation of
Yang H; Zhang C; Yuan Z; Rodriguez-Rodriguez C; Robertson A; Radchenko V; Perron R; Gendron D; Causey P; Gao F; Bénard F; Schaffer P
Chemistry; 2020 Sep; 26(50):11435-11440. PubMed ID: 32588455
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Hofman MS; Lawrentschuk N; Francis RJ; Tang C; Vela I; Thomas P; Rutherford N; Martin JM; Frydenberg M; Shakher R; Wong LM; Taubman K; Ting Lee S; Hsiao E; Roach P; Nottage M; Kirkwood I; Hayne D; Link E; Marusic P; Matera A; Herschtal A; Iravani A; Hicks RJ; Williams S; Murphy DG;
Lancet; 2020 Apr; 395(10231):1208-1216. PubMed ID: 32209449
[TBL] [Abstract][Full Text] [Related]
28. Development of
Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S
Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889
[TBL] [Abstract][Full Text] [Related]
29.
Sachpekidis C; Afshar-Oromieh A; Kopka K; Strauss DS; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):592-602. PubMed ID: 31728588
[TBL] [Abstract][Full Text] [Related]
30. PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy.
Wester HJ; Schottelius M
Semin Nucl Med; 2019 Jul; 49(4):302-312. PubMed ID: 31227053
[TBL] [Abstract][Full Text] [Related]
31. Effects of Linker Modification on Tumor-to-Kidney Contrast of
Kuo HT; Pan J; Zhang Z; Lau J; Merkens H; Zhang C; Colpo N; Lin KS; Bénard F
Mol Pharm; 2018 Aug; 15(8):3502-3511. PubMed ID: 29920108
[No Abstract] [Full Text] [Related]
32. Synthesis, Characterization, and Initial Biological Evaluation of [
Gao F; Sihver W; Bergmann R; Belter B; Bolzati C; Salvarese N; Steinbach J; Pietzsch J; Pietzsch HJ
ChemMedChem; 2018 Jun; 13(11):1146-1158. PubMed ID: 29659163
[TBL] [Abstract][Full Text] [Related]
33. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
34. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.
Hofman MS; Hicks RJ; Maurer T; Eiber M
Radiographics; 2018; 38(1):200-217. PubMed ID: 29320333
[TBL] [Abstract][Full Text] [Related]
35.
Iravani A; Hofman MS; Mulcahy T; Williams S; Murphy D; Parameswaran BK; Hicks RJ
Cancer Imaging; 2017 Dec; 17(1):31. PubMed ID: 29268784
[TBL] [Abstract][Full Text] [Related]
36. Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers.
Kopka K; Benešová M; Bařinka C; Haberkorn U; Babich J
J Nucl Med; 2017 Sep; 58(Suppl 2):17S-26S. PubMed ID: 28864607
[TBL] [Abstract][Full Text] [Related]
37. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.
Sheikhbahaei S; Afshar-Oromieh A; Eiber M; Solnes LB; Javadi MS; Ross AE; Pienta KJ; Allaf ME; Haberkorn U; Pomper MG; Gorin MA; Rowe SP
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2117-2136. PubMed ID: 28765998
[TBL] [Abstract][Full Text] [Related]
38. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.
Giesel FL; Hadaschik B; Cardinale J; Radtke J; Vinsensia M; Lehnert W; Kesch C; Tolstov Y; Singer S; Grabe N; Duensing S; Schäfer M; Neels OC; Mier W; Haberkorn U; Kopka K; Kratochwil C
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):678-688. PubMed ID: 27889802
[TBL] [Abstract][Full Text] [Related]
39. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer.
Afshar-Oromieh A; Babich JW; Kratochwil C; Giesel FL; Eisenhut M; Kopka K; Haberkorn U
J Nucl Med; 2016 Oct; 57(Suppl 3):79S-89S. PubMed ID: 27694178
[TBL] [Abstract][Full Text] [Related]
40. PET/CT is a cost-effective tool against cancer: synergy supersedes singularity.
Fischer BM; Siegel BA; Weber WA; von Bremen K; Beyer T; Kalemis A
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1749-52. PubMed ID: 27178271
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
